Ongoing clinical trials include the use of GC33 (codrituzumab), an anti-GPC3 antibody which has been found to debilitate cancer cells via antibody-dependent cellular cytotoxicity and/or complement-dependent cytotoxicity and has shown prognostic merit for HCC patients in phase II trials. Here, GPC3 is linked to hepatocellular carcinoma.